Xilio director granted 5,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xilio Therapeutics director Robert W. Ross received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $7.99 per share and expires on June 10, 2036. It will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, assuming he remains in service. This is a compensation-related award, not an open-market share purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 5,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Key Figures
Key Terms
Stock Option (right to buy) financial
exercise price financial
vesting financial
annual meeting of stockholders financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Xilio Therapeutics (XLO) report for Robert W. Ross?
What is the exercise price and expiration date of Robert W. Ross’s Xilio (XLO) options?
When do Robert W. Ross’s Xilio Therapeutics (XLO) stock options vest?
Is Robert W. Ross’s Form 4 transaction in Xilio (XLO) a stock purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.